New Zealand markets close in 4 hours 4 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.82-0.53 (-5.67%)
At close: 04:00PM EST
8.69 -0.13 (-1.47%)
After hours: 06:40PM EST

Seres Therapeutics, Inc.

200 Sidney Street
4th Floor
Cambridge, MA 02139
United States
617 945 9626

Full-time employees155

Key executives

NameTitlePayExercisedYear born
Mr. Eric D. Shaff M.B.A.Pres, CEO & Director1.09MN/A1976
Dr. David S. Ege Ph.D.Exec. VP & Chief Technology Officer142.71kN/A1974
Mr. Thomas J. DesRosierChief Legal Officer, Exec. VP & Sec.719.55kN/A1955
Mr. David A. Arkowitz M.B.A.Exec. VP, CFO & Head of Bus. Devel.N/AN/A1961
Dr. Matthew R. Henn Ph.D.Exec. VP & Chief Scientific OfficerN/AN/A1975
Mr. Carlo TanziVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Jeff YorkVP of HRN/AN/AN/A
Ms. Jayne M. GanslerExec. VP & Chief People OfficerN/AN/AN/A
Dr. John G. Aunins Ph.D.Sr. AdvisorN/AN/A1961
Mr. James R. WestonSr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Seres Therapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.